In vivo role of checkpoint kinase 2 in signaling telomere dysfunction
Article first published online: 12 JUN 2014
© 2014 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Volume 13, Issue 5, pages 810–816, October 2014
How to Cite
García-Beccaria, M., Martínez, P., Flores, J. M. and Blasco, M. A. (2014), In vivo role of checkpoint kinase 2 in signaling telomere dysfunction. Aging Cell, 13: 810–816. doi: 10.1111/acel.12237
- Issue published online: 19 SEP 2014
- Article first published online: 12 JUN 2014
- Manuscript Accepted: 11 MAY 2014
- European Research Council (ERC). Grant Number: GA#232854
- European Union FP7 Projects. Grant Numbers: 2007-A-20088, 2010-259749
- Spanish Ministry of Economy and Competitiveness Projects. Grant Numbers: SAF2008-05384, CSD2007-00017
- Regional of Government of Madrid Project. Grant Number: S2010/BMD-2303
- AXA Research Fund
- Fundación Lilly, Spain
- Fundación Botín, Spain
- DNA damage;
Checkpoint kinase 2 (CHK2) is a downstream effector of the DNA damage response (DDR). Dysfunctional telomeres, either owing to critical shortening or disruption of the shelterin complex, activate a DDR, which eventually results in cell cycle arrest, senescence and/or apoptosis. Successive generations of telomerase-deficient (Terc) mice show accelerated aging and shorter lifespan due to tissue atrophy and impaired organ regeneration associated to progressive telomere shortening. In contrast, mice deficient for the shelterin component TRF1 in stratified epithelia show a rapid and massive induction of DDR, leading to perinatal lethality and severe skin defects. In both mouse models, p53 deficiency can rescue survival. Here, we set to address the role of CHK2 in signaling telomere dysfunction in both mouse models. To this end, we generated mice doubly deficient for Chk2 and either Terc (Chk2−/− Terc−/−) or Trf1 (Trf1Δ/Δ K5Cre Chk2−/−). We show that Chk2 deletion improves Terc-associated phenotypes, including lifespan and age-associated pathologies. Similarly, Chk2 deficiency partially rescues perinatal mortality and attenuates degenerative pathologies of Trf1Δ/Δ K5Cre mice. In both cases, we show that the effects are mediated by a significant attenuation of p53/p21 signaling pathway. Our results represent the first demonstration of a role for CHK2 in the in vivo signaling of dysfunctional telomeres.